## Linda Kwakkenbos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3148788/publications.pdf

Version: 2024-02-01

448610 406436 87 1,628 19 35 citations g-index h-index papers 89 89 89 2219 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	1.5	4
2	Reporting transparency and completeness in Trials: Paper 2 - reporting of randomised trials using registries was often inadequate and hindered the interpretation of results. Journal of Clinical Epidemiology, 2022, 141, 175-186.	2.4	8
3	Reporting transparency and completeness in trials: Paper 4 - reporting of randomised controlled trials conducted using routinely collected electronic records – room for improvement. Journal of Clinical Epidemiology, 2022, 141, 198-209.	2.4	7
4	Reporting transparency and completeness in trials: Paper 3 – trials conducted using administrative databases do not adequately report elements related to use of databases. Journal of Clinical Epidemiology, 2022, 141, 187-197.	2.4	7
5	The patient engagement evaluation tool was valid for clinical practice guideline development. Journal of Clinical Epidemiology, 2022, 143, 61-72.	2.4	8
6	Mental health before and during the pandemic in people with systemic sclerosis. Lancet Rheumatology, The, 2022, 4, e82-e85.	2.2	9
7	Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. Lancet Rheumatology, The, 2022, 4, e243-e246.	2.2	9
8	Trajectories of adjustment disorder symptoms in post-treatment breast cancer survivors. Supportive Care in Cancer, 2022, 30, 3521-3530.	1.0	2
9	Prospective longitudinal study on fear of cancer recurrence in patients newly diagnosed with head and neck cancer: Course, trajectories, and associated factors. Head and Neck, 2022, 44, 914-925.	0.9	14
10	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	0.5	3
11	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	1.2	9
12	Reasons for not participating in scleroderma patient support groups: a comparison of results from the North American and European scleroderma support group surveys. Disability and Rehabilitation, 2021, 43, 1279-1286.	0.9	6
13	Effects of cosmetic and other camouflage interventions on appearance-related and psychological outcomes among adults with visible differences in appearance: a systematic review. BMJ Open, 2021, 11, e046634.	0.8	1
14	CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ, The, 2021, 373, n857.	3.0	65
15	Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). BMJ Open, 2021, 11, e049093.	0.8	9
16	Effects of non-pharmacological and non-surgical interventions on health outcomes in systemic sclerosis: protocol for a living systematic review. BMJ Open, 2021, 11, e047428.	0.8	3
17	Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. Lancet Rheumatology, The, 2021, 3, e427-e437.	2.2	24
18	A study protocol for the development of a SPIRIT extension for trials conducted using cohorts and routinely collected data (SPIRIT-ROUTINE). HRB Open Research, 2021, 4, 82.	0.3	4

#	Article	IF	Citations
19	Pain and Self-Efficacy Among Patients With Systemic Sclerosis. Nursing Research, 2021, 70, 334-343.	0.8	3
20	Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. BMJ Open, 2021, 11, e042404.	0.8	3
21	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	0.7	4
22	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatology, The, 2021, 3, e844-e854.	2.2	9
23	Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study. Journal of Psychosomatic Research, 2020, 139, 110271.	1.2	20
24	Not as Stable as We Think: A Descriptive Study of 12 Monthly Assessments of Fear of Cancer Recurrence Among Curatively-Treated Breast Cancer Survivors 0–5 Years After Surgery. Frontiers in Psychology, 2020, 11, 580979.	1.1	16
25	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal of Psychosomatic Research, 2020, 139, 110262.	1.2	25
26	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	1,2	21
27	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	0.5	7
28	Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma atient-centred Intervention Network (SPIN) Cohort Study. BMJ Open, 2020, 10, e037639.	0.8	1
29	Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma atient-centred Intervention Network (SPIN) Cohort Study. BMJ Open, 2020, 10, e037639.	0.8	3
30	Systematic review of body image measures. Body Image, 2019, 30, 170-211.	1.9	97
31	Reasons for attending support groups and organizational preferences: A replication study using the North American Scleroderma Support Group Survey. Journal of Scleroderma and Related Disorders, 2019, 4, 173-186.	1.0	7
32	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	0.9	0
33	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. Journal of Rheumatology, 2019, 46, 1605-1613.	1.0	11
34	The Scleroderma Research Topics Survey for patients and health care professionals: A Scleroderma Patient-centered Intervention Network Project. Journal of Scleroderma and Related Disorders, 2019, 4, 165-172.	1.0	2
35	Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. BMJ Open, 2019, 9, e024010.	0.8	13
36	Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. BMJ Open, 2019, 9, e029542.	0.8	5

#	Article	IF	Citations
37	Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program. Trials, 2019, 20, 717.	0.7	8
38	Don't forget about the "R―in cmRCT: reply to Groenwold and van Smeden. Journal of Clinical Epidemiology, 2019, 106, 143-144.	2.4	1
39	Reasons for attending support groups and organizational preferences: the European scleroderma support group members survey. Disability and Rehabilitation, 2019, 41, 974-982.	0.9	13
40	Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale. Journal of Scleroderma and Related Disorders, 2018, 3, 106-111.	1.0	2
41	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	1.5	8
42	Addressing overestimation of the prevalence of depression based on self-report screening questionnaires. Cmaj, 2018, 190, E44-E49.	0.9	139
43	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1557-1562.	1.5	17
44	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating $\hat{a} \in \hat{a}$ not applicable $\hat{a} \in \hat{a}$ responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. BMJ Open, 2018, 8, e018641.	0.8	4
45	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. Disability and Rehabilitation, 2018, 40, 1997-2003.	0.9	17
46	Reasons for Not Participating in Scleroderma Patient Support Groups: A Crossâ€Sectional Study. Arthritis Care and Research, 2018, 70, 275-283.	1.5	13
47	Understanding coping strategies among people living with scleroderma: a focus group study. Disability and Rehabilitation, 2018, 40, 3012-3021.	0.9	8
48	Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. Research Integrity and Peer Review, 2018, 3, 9.	2.2	28
49	Reâ€validation and screening capacity of the 6â€item version of the Cancer Worry Scale. Psycho-Oncology, 2018, 27, 2609-2615.	1.0	43
50	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol. Journal of Scleroderma and Related Disorders, 2018, 3, 91-97.	1.0	7
51	Validation of the Social Interaction Anxiety Scale in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort study. Journal of Scleroderma and Related Disorders, 2018, 3, 98-105.	1.0	3
52	Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. BMJ Open, 2018, 8, e025266.	0.8	10
53	Structural validation of the Self-Compassion Scale with a German general population sample. PLoS ONE, 2018, 13, e0190771.	1.1	59
54	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	0.9	53

#	Article	IF	CITATIONS
55	The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 88-94.	0.4	3
56	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	1.9	3
57	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	0.9	51
58	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. Clinical Rheumatology, 2017, 36, 373-379.	1.0	9
59	Assessment of English–French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. Body Image, 2017, 22, 97-102.	1.9	5
60	Comparison of Self-Efficacy for Managing Chronic Disease between patients with systemic sclerosis and other chronic conditions: a systematic review. Rheumatology International, 2017, 37, 281-292.	1.5	8
61	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 57-63.	1.0	2
62	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 48-55.	0.4	2
63	Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions. PLoS ONE, 2016, 11, e0153220.	1.1	80
64	Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. PLoS ONE, 2016, 11, e0152419.	1.1	22
65	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	1.5	31
66	Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. Arthritis Care and Research, 2016, 68, 1143-1149.	1.5	10
67	Using Optimal Test Assembly Methods for Shortening Patientâ€Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scaleâ€6: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1704-1713.	1.5	23
68	Development and Validation of the Body Concealment Scale for Scleroderma. Arthritis Care and Research, 2016, 68, 1158-1165.	1.5	11
69	Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 92-99.	0.4	3
70	Effectiveness of Nonpharmacologic Interventions in Systemic Sclerosis: A Systematic Review. Arthritis Care and Research, 2015, 67, 1426-1439.	1.5	53
71	Psychosocial Aspects of Scleroderma. Rheumatic Disease Clinics of North America, 2015, 41, 519-528.	0.8	58
72	Major Depression Diagnoses Among Patients With Systemic Sclerosis: Baseline and Oneâ€Month Followup. Arthritis Care and Research, 2015, 67, 411-416.	1.5	26

#	Article	IF	CITATIONS
73	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 1156-1162.	1.0	5
74	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. PLoS ONE, 2014, 9, e91979.	1.1	13
75	Cognitive-Behavioural Therapy Targeting Fear of Progression in an Interdisciplinary Care Program: A Case Study in Systemic Sclerosis. Journal of Clinical Psychology in Medical Settings, 2014, 21, 297-312.	0.8	4
76	Prevalence of posttraumatic stress disorder (PTSD) in women with breast cancer. Journal of Psychosomatic Research, 2014, 76, 485-486.	1.2	15
77	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. PLoS ONE, 2014, 9, e102897.	1.1	9
78	Reassessing the clinical utility of the Patient Health Questionnaire (PHQ)-9 for depression screening in prenatal women: a commentary on Sidebottom et al Archives of Women's Mental Health, 2013, 16, 253-254.	1.2	1
79	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	0.8	104
80	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients. PLoS ONE, 2013, 8, e53923.	1.1	14
81	Health care use and patients' perceptions on quality of care in systemic sclerosis. Clinical and Experimental Rheumatology, 2013, 31, 64-70.	0.4	9
82	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. Journal of Psychosomatic Research, 2012, 72, 199-204.	1.2	54
83	Validity of the Fear of Progression Questionnaireâ€Short Form in patients with systemic sclerosis. Arthritis Care and Research, 2012, 64, 930-934.	1.5	34
84	Addressing patient health care demands in systemic sclerosis: pre-post assessment of a psycho-educational group programme. Clinical and Experimental Rheumatology, 2011, 29, S60-5.	0.4	6
85	Psychological health and wellâ€being in systemic sclerosis: State of the science and consensus research agenda. Arthritis Care and Research, 2010, 62, 1181-1189.	1.5	79
86	Validation of the "knowledge about melanoma early detection scale―in a sample of melanoma survivors. Current Psychology, 0, , 1.	1.7	0
87	Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma <scp>Patientâ€Centered</scp> Intervention Network Cohort Study. ACR Open Rheumatology, 0, , .	0.9	O